Third Harmonic Bio, Inc. THRD
Institutional shares held
35.8 Million
0
calls
0
puts
Total value of holdings
$499M
$0
calls
$0
puts
Market Cap
$562M
40,328,900
Shares Out.
Institutional ownership
88.72%
# of Institutions
68
We take great care to ensure that the data presented and summarized in this overview for Third Harmonic Bio, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding THRD
View all-
Atlas Venture Life Science Advisors, LLC10.9MShares$152 Million12.88% of portfolio
-
Orbimed Advisors LLC San Diego, CA5.78MShares$80.6 Million1.23% of portfolio
-
Bvf Inc San Francisco, CA4.37MShares$60.9 Million1.23% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA3.18MShares$44.4 Million0.86% of portfolio
-
General Atlantic LLC New York, NY2.96MShares$41.2 Million0.65% of portfolio
-
Boxer Capital, LLC San Diego, CA2MShares$27.9 Million0.98% of portfolio
-
Black Rock Inc. New York, NY1.36MShares$19 Million0.0% of portfolio
-
Commodore Capital LP New York, NY1.25MShares$17.4 Million1.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA851KShares$11.9 Million0.0% of portfolio
-
Jpmorgan Chase & CO New York, NY442KShares$6.16 Million0.0% of portfolio
Latest Institutional Activity in THRD
Top Purchases
Top Sells
About THRD
Insider Transactions at THRD
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 26
2024
|
Julie Person CHIEF ADMINISTRATIVE OFFICER |
SELL
Open market or private sale
|
Direct |
10,000
-100.0%
|
$120,000
$12.46 P/Share
|
|
Jun 26
2024
|
Julie Person CHIEF ADMINISTRATIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+50.0%
|
$40,000
$4.2 P/Share
|
|
Jun 07
2024
|
Jennifer Dittman Chief Development Oper Officer |
SELL
Open market or private sale
|
Direct |
494
-100.0%
|
$6,916
$14.17 P/Share
|
|
Jun 07
2024
|
Jennifer Dittman Chief Development Oper Officer |
SELL
Grant, award, or other acquisition
|
Direct |
494
-50.0%
|
$1,976
$4.2 P/Share
|
|
May 20
2024
|
Jennifer Dittman Chief Development Oper Officer |
SELL
Open market or private sale
|
Direct |
1,042
-100.0%
|
$14,588
$14.0 P/Share
|
|
May 20
2024
|
Jennifer Dittman Chief Development Oper Officer |
SELL
Grant, award, or other acquisition
|
Direct |
1,042
-50.0%
|
$4,168
$4.3 P/Share
|
|
May 16
2024
|
Jennifer Dittman Chief Development Oper Officer |
SELL
Open market or private sale
|
Direct |
23,578
-100.0%
|
$330,092
$14.04 P/Share
|
|
May 16
2024
|
Jennifer Dittman Chief Development Oper Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,578
+36.33%
|
$94,312
$4.25 P/Share
|
|
May 09
2024
|
Natalie C. Holles CEO |
SELL
Open market or private sale
|
Direct |
20,222
-1.63%
|
$242,664
$12.18 P/Share
|
|
May 09
2024
|
Natalie C. Holles CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,222
+1.61%
|
$80,888
$4.2 P/Share
|
|
Apr 11
2024
|
Natalie C. Holles CEO |
SELL
Open market or private sale
|
Direct |
13,558
-1.1%
|
$162,696
$12.19 P/Share
|
|
Apr 11
2024
|
Natalie C. Holles CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
13,558
+1.09%
|
$54,232
$4.2 P/Share
|
|
Apr 04
2024
|
Julie Person CHIEF ADMINISTRATIVE OFFICER |
SELL
Open market or private sale
|
Direct |
1,107
-100.0%
|
$11,070
$10.0 P/Share
|
|
Apr 04
2024
|
Julie Person CHIEF ADMINISTRATIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,107
+50.0%
|
$4,428
$4.2 P/Share
|
|
Dec 05
2023
|
Julie Person CHIEF ADMINISTRATIVE OFFICER |
SELL
Open market or private sale
|
Direct |
12,863
-100.0%
|
$128,630
$10.3 P/Share
|
|
Dec 05
2023
|
Julie Person CHIEF ADMINISTRATIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
12,863
+50.0%
|
$51,452
$4.2 P/Share
|
|
Dec 05
2023
|
Edward R. Conner Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,790
-100.0%
|
$47,900
$10.03 P/Share
|
|
Dec 05
2023
|
Edward R. Conner Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,790
+50.0%
|
$19,160
$4.2 P/Share
|
|
Dec 20
2022
|
Bvf Partners L P > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
214,063
+4.44%
|
$856,252
$4.11 P/Share
|
|
Sep 19
2022
|
David P Bonita |
BUY
Open market or private purchase
|
Indirect |
300,000
+4.94%
|
$5,100,000
$17.0 P/Share
|
Last 12 Months Summary
Buy / Acquisition
86.1K
Shares
From
4
Insiders
| Exercise of conversion of derivative security | 62.5K shares |
|---|---|
| Grant, award, or other acquisition | 23.6K shares |
Sell / Disposition
89.2K
Shares
From
5
Insiders
| Open market or private sale | 87.7K shares |
|---|---|
| Grant, award, or other acquisition | 1.54K shares |